Biomaterials Science

ROYAL SOCIETY OF CHEMISTRY

CORRECTION

View Article Online
View Journal | View Issue

Cite this: *Biomater. Sci.*, 2021, **9**, 6966

DOI: 10.1039/d1bm90082j

rsc.li/biomaterials-science

Correction: Recent development of gene therapy for pancreatic cancer using non-viral nanovectors

Yu Liu,[a] Wei Wu,[a] Yiyao Wang,[b] Shisong Han,[c] Yuanyuan Yuan,[d] Jinsheng Huang,*[b] Xintao Shuai*[c] and Peng Zhao*[a]

Correction for 'Recent development of gene therapy for pancreatic cancer using non-viral nanovectors' by Yu Liu *et al.*, *Biomater. Sci.*, 2021, DOI: 10.1039/d1bm00748c.

The authors regret that Peng Zhao's name was incorrectly spelled in the original article. The full and correct spelling is as shown above. In addition, the authors regret the omission of copyright statements in the captions for Fig. 5–9 in the original article. The authors confirm they have obtained copyright permissions for Fig. 5–9 and the updated captions to reflect this are as shown below.



Fig. 5 (A) The preparation of polyarginine-based nanoparticles carrying miRNA-212 and doxorubicin for cell-penetrating drug delivery, resulting in efficient xenograft PC treatment. (B) The peptide sequence of PL-1 and SP-94dr.[1] Abbreviations: Arg, arginine; PL-1, plectin-1; and SP-94dr, USP9X gene linking nine D-arginine residues by four-glycine. Reproduced with permission from Elsevier.[1]

[a]*Department of Medical Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. E-mail: zhaop@zju.edu.cn*
[b]*Department of Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China. E-mail: huangjsh55@mail.sysu.edu.cn*
[c]*PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou, 510275, China. E-mail: shuaixt@mail.sysu.edu.cn*
[d]*School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China*



Fig. 6 Scheme of a ROS-responsive PEG-*b*-PAEBEA nanoplatform co-loaded with miRNA-34a and PLK1 inhibitor volasertib (BI6727) for the treatment of PDAC.[2] Abbreviations: PEG-*b*-PAEBEA, poly(ethylene glycol)-poly[aspartamidoethyl(*p*-boronobenzyl)diethylammonium bromide]; miR-34a, miRNA-34a; PLK1, Polo-like kinase 1; C-myc, cellular-myelocytomatosis viral oncogene; Bcl-2, B cell lymphoma/lewkmia-2; and ROS, reactive oxygen species. Reproduced with permission from the American Chemical Society.[2]



Fig. 7 Schematic illustration of the preparation of NP-GEM-siRRM2 for the chemotherapy and RNAi therapy of RRM2-overexpressed PC in mice.[3] Abbreviations: GEM, gemcitabine; NP, nanoparticle; and RRM2, ribonucleotide reductase subunit 2. Reproduced with permission from Elsevier.[3]



Fig. 8 pH sensitivity and synergistic anti-tumor performance of ^{LY}iCluster$_{siPD\text{-}L1}$. (A) The preparation and sensitivity to tumor acidic extracellular environment (pHe) of ^{LY}iCluster$_{siPD\text{-}L1}$. (B) The tumor accumulation and anti-tumor performance of ^{LY}iCluster$_{siPD\text{-}L1}$. LY2157299 decreased the extracellular matrix when synergized with siPD-L1 to promote the tumor infiltration of CD8+ T cells.[4] Abbreviations: PCL-CDM-PAMAM, poly(amidoamine)-grafted poly(caprolactone) *via* a pH-sensitive CDM linker; siPD-L1, siRNA against PD-L1; PSC, pancreatic stellate cell; and ECM, extracellular matrix. Reproduced with permission from the Royal Society of Chemistry.[4]



Fig. 9 Schematic illustration of the preparation of GQD/DOX/BCPV/K-Ras siRNA nanocomplexes for tri-model therapy (a combination of chemotherapy, PTT, and gene therapy) of PC.[5] Abbreviations: GQD, graphene quantum dot; DOX, doxorubicin; and BCPV, biodegradable charged polyester vector. Reproduced with permission from the American Chemical Society.[5]

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

References

1 W. Chen, Y. Zhou, X. Zhi, T. Ma, H. Liu, B. W. Chen, X. Zheng, S. Xie, B. Zhao, X. Feng, X. Dang and T. Liang, *Biomaterials*, 2019, **192**, 590–600.
2 X. F. Xin, F. Lin, Q. Y. Wang, L. F. Yin and R. I. Mahato, *ACS Appl. Mater. Interfaces*, 2019, **11**, 14647–14659.
3 X. Zhao, X. Wang, W. Sun, K. Cheng, H. Qin, X. Han, Y. Lin, Y. Wang, J. Lang, R. Zhao, X. Zheng, Y. Zhao, J. Shi, J. Hao, Q. R. Miao, G. Nie and H. Ren, *Biomaterials*, 2018, **158**, 44–55.
4 Y. Wang, Z. X. Gao, X. J. Du, S. B. Chen, W. C. Zhang, J. L. Wang, H. J. Li, X. Y. He, J. Cao and J. Wang, *Biomater. Sci.*, 2020, **8**, 5121–5132.
5 C. B. Yang, K. K. Chan, G. X. Xu, M. J. Yin, G. M. Lin, X. M. Wang, W. J. Lin, M. D. Birowosuto, S. W. Zeng, T. Ogi, K. Okuyama, F. A. Permatasari, F. Iskandar, C. K. Chen and K. T. Yong, *ACS Appl. Mater. Interfaces*, 2019, **11**, 2768–2781.